Core Viewpoint - The company has reported significant growth in its third-quarter performance, with a focus on enhancing its core business and expanding into international markets, while also undergoing governance changes by eliminating the supervisory board [2][3][26]. Financial Performance - The company's third-quarter revenue increased by 17.71% compared to the previous quarter [2]. - New orders increased by 29.37% year-on-year, with a notable 30.71% growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA) [2]. - The total order amount on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [2]. Market Expansion - The company has established diverse marketing channels to enhance its international market presence, resulting in a significant increase in new orders from overseas markets [3]. - The focus on innovative drug development includes high-potential areas such as CAR-T, small nucleic acids, and multi-specific antibodies, with substantial growth in contract amounts for these innovative categories [3]. Governance Changes - The company plans to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with the new Company Law effective from July 1, 2024 [26][27]. - Amendments to the company's articles of association will reflect this governance change and other necessary updates [28][29].